PRESS RELEASE
McDermott Launches Unified Patent Court Resource Center
March 1, 2023
Read time: 4 min
International law firm McDermott Will & Emery launched its new online Unified Patent Court Resource Center in preparation for the official installment of the Unified Patent Court (UPC) and the European patent with unitary effect (Unitary Patent). The UPC will launch on June 1, 2023, and will transform patent enforcement in Europe.
“The UPC brings a fresh look at global patents under review in a new court system, creating many new risks, incentives and opportunities for clients and their businesses. Our team is prepared to help those looking for guidance and action,” said Chuck Larsen, Boston-based partner in McDermott’s intellectual property (IP) practice. As a US lawyer and English solicitor, Chuck is licensed to practice before the European Patent Office and the courts of England and Wales.
The Resource Center is a one-stop location for thought leadership and insights that explain the timeline of the UPC launch and relevant corporate action items. It also addresses future conversations regarding changes to the law, precedent-setting litigation that comes before the court and information on how this court will shape the global patent landscape.
“This is the start of revolutionary change within the European Union, and I am excited for the possibility of a new wave of patent evolution,” said Hon.-Prof. Dr. Henrik Holzapfel, Düsseldorf-based IP partner. “Our IP lawyers develop robust cross-border strategies specific to our clients, whether they are looking to file infringement or revocation actions in the UPC, as well as advising our clients on the impact of the UPC system on license and R&D agreements. Our team is also well-versed in the process of filing and obtaining unitary patents.”
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
Media Contact
McDermott Advises Claris Ventures in a EUR 10m Investment Round in Resalis Therapeutics
DEAL ANNOUNCEMENT / PRESS RELEASE
McDermott Advises Claris Ventures in a EUR 10m Investment Round in Resalis Therapeutics
March 1, 2023
Read time: 3 min
International law firm McDermott Will & Emery represented Claris Ventures SGR in its equity investment in a EUR 10 million seed round in Resalis Theraputics, a biotech startup whose transformative metabolic disease approach targets a master regulator of multiple pathways underlying obesity and fatty liver disease.
Resalis Therapeutics is a scale-up operating in Italy. The funding will support the finalization of IND-enabling studies for the company’s lead program, RES-010, which Resalis will initially develop as a novel treatment for obesity and nonalcoholic fatty liver disease (NAFLD).
Claris Ventures, through its funds “Claris Biotech I” and “Claris Biotech I – Parallel Fund”, was the lead investor of the round, backed by Italian Angels for Growth and Club degli Investitori.
McDermott Will & Emery Studio Legale Associato assisted Claris Ventures in all legal aspects of the transaction, with partners Ettore Scandale and Fabrizio Faina (first closing) and associate Stefano Pardini, supported by trainee Matteo Landini (second closing).
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
Media Contact
McDermott advised eureKARE’s Biomedical Start-up Studio on the the Creation of EonBio, a New Biotech Company Co-Founded with Yeda that will Revolutionize Drug Discovery with Pioneering Cell-free Technology on a Chip
DEAL ANNOUNCEMENT / PRESS RELEASE
McDermott advised eureKARE’s Biomedical Start-up Studio on the the Creation of EonBio, a New Biotech Company Co-Founded with Yeda that will Revolutionize Drug Discovery with Pioneering Cell-free Technology on a Chip
February 27, 23
Read time: 2 min
McDermott Will & Emery has advised eureKARE, investment company focused on financing and developing synthetic biology innovation across Europe, for the creation of EonBio, co-founded with Yeda, the commercial arm of the Weizmann Institute of Science in Israël, which has granted an exclusive license to EonBio under its “cell free technology” platform.
EonBio will further develop the “cell free technology platform”, a cutting-edge platform, to address high unmet medical need by reconstructing intricate bioproduction systems akin to the ones found in living cell.
The McDermott team that advised eureKARE was composed of Emmanuelle Trombe, partner, Anne-France Moreau, partner and Caroline Noyrez, lawyer (Transaction / Life Sciences)
Media Contact
McDermott Will & Emery Advised Montefiore Investment on the Sale of its Shares in Gandi to Total Webhosting Solutions
DEAL ANNOUNCEMENT / PRESS RELEASE
McDermott Will & Emery Advised Montefiore Investment on the Sale of its Shares in Gandi to Total Webhosting Solutions
February 24, 2023
Read time: 3 min
McDermott Will & Emery advised Montefiore Investment, a leading fund for mid-cap companies, in the sale of its stake in Gandi, a French domain name registration, web hosting, email and SSL certificate provider, to the pan-European company Total Webhosting Solutions (TWS).
The two companies announced their merger and the creation of Your.Online: a leading European online services platform that helps companies of all sizes realize and grow their online ambitions. Your.Online will serve over one million customers in Europe and the United States.
The McDermott team that advised Montefiore Investment included:
– Grégoire Andrieux, Fabrice Piollet, Partners, Marie-Muriel Barthelet, Counsel, Julien-Pierre Tannoury, Constance Muller and Charline Boulenger, Associates, on the Corporate aspects
– Charlotte Michellet, Counsel, on the Regulatory aspects
Media Contact
McDermott Will & Emery advised MML on its Investment in Kickmaker
DEAL ANNOUNCEMENT / PRESS RELEASE
McDermott Will & Emery advised MML on its Investment in Kickmaker
February 23, 2023
Read time: 3 min
McDermott Will & Emery advised MML in its acquisition of an equity stake in Kickmaker, the first consulting firm specialized in engineering and outsourced product development in France.
In this transaction, MML joined forces with co-investor Bpifrance and benefited from a significant reinvestment from existing investor Generis Capital Partners.
Through this transaction, Kickmaker, which is present in the United States, intends to expand its activities in that country, while strengthening its focus on eco-design and decarbonization of industry, WEB3 and industrial design.
The McDermott team that advised MML included:
• Henri Pieyre de Mandiargues, partner, Antoine Ricol, counsel, and Julien-Pierre Tannoury, associate on corporate aspects,
• Romain Desmonts, partner, and Paul-Henry de Laguiche, associate, on tax law,
• Charlotte Michellet, counsel, and Benoit Feroldi, associate, on public/regulatory law.
Media Contact
McDermott Grows Austin Office with Healthcare Partner
PRESS RELEASE
McDermott Grows Austin Office with Healthcare Partner
February 23, 2023
Read time: 4 min
International law firm McDermott Will & Emery is pleased to announce Austin-based Jay Greathouse has joined as a partner in the Firm’s Healthcare Practice Group. Jay has a broad practice representing for-profit and nonprofit healthcare organizations, as well as healthcare industry investors, in their most significant transactions.
“Texas has seen explosive growth across the healthcare industry over the last few years—including increased development of healthcare facilities, hospitals, health systems and managed care companies,” said McDermott’s Global Head of Healthcare Jerry Sokol. “This resulted in prioritizing the growth of our healthcare practice in Texas. Jay is a highly skilled deal lawyer leading client teams from this key geographic market, and we’re thrilled to welcome him to our team.”
“Jay is a natural leader and strongly compliments our growing Austin footprint, particularly at the intersection of healthcare, technology and IP,” said Office Managing Partner of the Austin office, Kevin Meek.
Jay works with hospitals, physician groups, ambulatory surgery centers, portfolio companies and private equity firms to execute complex joint ventures, cross-border collaborations and transactions, acquisitions and divestitures. Jay also provides counsel on corporate governance matters for both established and early-stage healthcare companies, advising clients on shareholder disputes, fiduciary duty issues and other boardroom challenges.
“McDermott’s best-in-class healthcare platform has always been on my radar,” Jay noted. “I am excited to help grow the Firm’s healthcare presence in Texas and collaborate with my talented new colleagues across the United States.”
Prior to joining McDermott, Jay was a partner at Waller Lansden Dortch & Davis LLP. He received his BS from Texas A&M University and his JD from Washington University School of Law.
Jay is the most recent addition to the Firm’s healthcare practice, following the arrivals of Partners Nick Alarif, Alya Sulaiman, Heili Kim and Denise Burke, as well as Counsels Lester Perling and Purnima Boominathan.
McDermott is the nation’s leading healthcare law firm and the only healthcare practice to receive top national rankings from U.S. News – Best Lawyers “Best Law Firms,” Chambers USA, The Legal 500 US and Law360. The practice was also recognized by Chambers as “Healthcare Team of the Year” in 2010, 2013, 2017, 2019 and 2022. McDermott has also held the top spot in PitchBook’s League Tables as the most active firm for healthcare private equity since 2017.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
Media Contact
McDermott Will & Emery Advised Shareholders and Management of Porsolt Group on Apax Partners’ Majority Stake
DEAL ANNOUNCEMENT / PRESS RELEASE
McDermott Will & Emery Advised Shareholders and Management of Porsolt Group on Apax Partners’ Majority Stake
February 22, 2023
Read time: 3 min
McDermott Will & Emery has advised shareholders and management of Porsolt Group, on Apax Partners’ majority stake to support its growth strategy to become a global leader in preclinical services.
Apax’s investment, together with the management and current shareholders of the company, will allow Porsolt to further grow and implement its strategy to become a comprehensive preclinical service company, addressing the varying therapeutical areas of the global Pharma, Biotech, and research communities.
McDermott team was composed of :
• Emmanuelle Trombe, partner, on Life Sciences aspects
• Henri Pieyre de Mandiargues, partner, Fanny Rech, counsel, and Alice Sevestre, associate, on corporate aspects
• Pierre-Arnoux Mayoly, partner, Elizabeth Amzallag, associate, on financing aspects
• Jilali Maazouz, partner, Abdel Abdellah and Anne-Lorraine Méreaux, associates, on employment aspects
• Come de Saint Vincent, counsel, on tax aspects
Media Contact
McDermott Will & Emery Advised ODDO BHF on the Launch of the ODDO BHF Venture Capital Fund
DEAL ANNOUNCEMENT / PRESS RELEASE
McDermott Will & Emery Advised ODDO BHF on the Launch of the ODDO BHF Venture Capital Fund
February 22, 2023
Read time: 2 min
McDermott Will & Emery has advised ODDO BHF on the launch of the ODDO BHF Venture Capital Fund. The fund will invest in both venture capital funds and unlisted technology companies in America, Europe and Asia. The group is targeting a size of 200M€ for this fund.
ODDO BHF Venture Capital Fund will focus on three types of investments: primary, secondary and co-investment.
The McDermott team that advised ODDO BHF comprised:
• Guillaume Panuel, partner, Houda Bourrich and Bréa Kamtcheu, associates
Media Contact
McDermott Will & Emery Advises Luxempart on Investment Agreement to Acquire a Minority Interest in Kestrel Vision Group, Alongside Caravelle and Management
DEAL ANNOUNCEMENT / PRESS RELEASE
McDermott Will & Emery Advises Luxempart on Investment Agreement to Acquire a Minority Interest in Kestrel Vision Group, Alongside Caravelle and Management
February 20, 2023
Read time: 3 min
McDermott Will & Emery is advising Luxempart on an investment agreement to acquire a minority stake in Kestrel Vision, a leading global developer of quality control and inspection solutions for the rigid packaging industry.
Luxempart joins Kestrel Vision’s existing shareholders, including Caravelle, a prominent French family investor, and management.
The transaction, which remains subject to customary regulatory approvals, is expected to close at the end of March 2023 and is designed to strengthen the Group’s capital base to continue its growth strategy.
The McDermott team advising Luxempart consisted of:
• Henri Pieyre de Mandiargues, partner, Antoine Ricol, counsel, Boris Wolkoff, and Pénélope Renard, associates on corporate aspects,
• Antoine Vergnat, partner, and Côme de Saint Vincent, counsel on tax matters,
• Pierre-Arnoux Mayoly, partner, and Julie-Anne Thiébaut, associate on financing aspects,
• Jilali Maazouz, partner, Abdel Abdellah and Naré Arshakyan, associates on employment law,
• Sabine Naugès, partner, and Benoît Feroldi, associate on regulatory aspects,
• Laura Morelli, partner, and Charles de Raignac, associate, on intellectual property aspects,
• Romain Perray, partner and Hélène Adda, associate, on Tech and Data aspects
• Frédéric Pradelles, partner in competition (antitrust)
Media Contact
McDermott Advised Argos Wityu on the Sale of La Compagnie des Desserts to PAI Partners
DEAL ANNOUNCEMENT / PRESS RELEASE
McDermott Advised Argos Wityu on the Sale of La Compagnie des Desserts to PAI Partners
February 17, 2023
Read time: 3 min
McDermott Will & Emery advised Argos Wityu on the sale to PAI Partners of La Compagnie des Desserts, a producer of premium artisanal ice cream and premium frozen pastries. La Compagnie des Desserts distributes its products to more than 23,000 customers in the food service sector across Europe.
Argos Wityu acquired a major stake in La Compagnie des Dessert in 2016. During the many years of close cooperation between the management and Argos Wituy, Compagnie des Desserts has doubled its revenue reaching almost EUR 117 million. This partnership has also permitted external growth operations including three strategic acquisitions in the UK, Spain and France, allowing Compagnie des Dessert to develop new services and products such as takeaway sales and the use of environmentally responsible products.
On the seller’ side, Argos Wityu was advised by McDermott: on corporate aspect, the team was led by Bertrand Delafaye (Partner) with Marie-Muriel Barthelet (Counsel) and Sarah Louifi (Associate) and on employment aspect, by Abdel Abdellah (Associate) and Michèle Gueravetian (Associate).
